Nalaganje...
4CPS-170 Evaluation of zoledronic acid in the treatment of bone diseases with high risk of fractures
BACKGROUND: Zoledronic acid (ZOL) administered as a 5 mg intravenous infusion anually is indicated for the treatment of bone diseases such as Paget disease and osteoporosis with a high risk of fracture. It is strongly advised that patients treated with ZOL receive adequate calcium and vitamin D (cal...
Shranjeno v:
| izdano v: | Eur J Hosp Pharm |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMJ Group
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7535356/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.260 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|